medigraphic.com

2018, Número 3

<< Anterior Siguiente >>

Cir Cir 2018; 86 (3)


Perfil de expresión de Ki67 en lesiones melanocíticas palmoplantares: estudio de casos y controles

González-Ramírez RA, Barboza-Quintana O, Flores-Gutiérrez JP, de la Fuente-Villarreal D, Torres-López E, Ríos-Briones NI

Idioma: Español
Referencias bibliográficas: 44
Paginas: 250-254
Archivo PDF: 188.96 Kb.


RESUMEN

Introducción: El melanoma acral lentiginoso es una neoplasia maligna que afecta a población predominantemente no caucásica. Debido al diagnóstico tardío suele tener mal pronóstico, además de que se considera una neoplasia biológicamente más agresiva, incluso cuando se detecta tempranamente. Objetivo: Determinar la expresión de Ki67 en el melanoma acral lentiginoso invasor y compararla con los nevos acrales. Método: Estudio transversal, descriptivo, observacional. Se realizó inmunohistoquímica con marcador Ki67 en 17 biopsias de melanoma acral lentiginoso invasor (casos) y 17 biopsias de nevos palmoplantares (controles). Se determinó la expresión nuclear de Ki-67 y se comparó entre ambos grupos. Resultados: La media de expresión de Ki67 fue del 8.5% en el grupo control y del 34% en el grupo de melanomas, siendo esta diferencia estadísticamente significativa (p ‹ 0.0001). Discusión: La expresión de Ki67 en los melanomas acrales es considerablemente mayor que en los nevos acrales. El valor pronóstico del marcador Ki67 sigue siendo considerado controversial. Sin embargo, hay estudios en los que en combinación con otros marcadores se refuerza su valor pronóstico. Conclusiones: Por la gran diferencia en inmunorreactividad de Ki67 entre melanomas y nevos, la expresión de Ki67, referida como índice proliferativo, podría ser considerada como factor pronóstico incluso más objetivo que el índice mitótico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Reed RJ. Acral lentiginous melanoma. En: Hartmann W, Kay S, Reed RJ, editors. New concepts in surgical pathology of the skin. New York: Wiley; 1976. p. 89-90.

  2. Phan A, Touzet S, Dalle S, Ronger-Savlé S, Balme B, Thomas L. Acral lentiginous melanoma: a clinic-prognostic study of 126 cases. Br J Dermatol. 2006;155:561-9.

  3. Chang JW, Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC, et al. Malignant melanoma in Taiwan: a prognostic study of 181 cases. Melanoma Res. 2004;14:537-41.

  4. Hudson DA, Krige JE. Melanoma in black South Africans. J Am Coll Surg. 1995;180 65-71.

  5. Cascinelli N, Zurrida S, Galimberti V, Bartoli C, Bufalino R, Del Prato I, et al. Acral lentiginous melanoma. A histological type without prognostic significance. J Dermatol Surg Oncol. 1994;20:817-22.

  6. Kuchelmeister C, Schaumburg-Lever G, Garbe C. Acral cutaneous melanoma in Caucasians: clinical features, histopathology and prognosis in 112 patients. Br J Dermatol. 2000;143:275-80.

  7. Slingluff CL Jr, Vollmer R, Seigler HF. Acral melanoma: a review of 185 patients with identification of prognostic variables. J Surg Oncol. 1990;45:91-8.

  8. Green A, McCredie M, MacKie R, Giles G, Young P, Morton C, et al. A case-control study of melanomas of the soles and palms (Australia and Scotland). Cancer Causes Control. 1999;10:21-5.

  9. Bormann G, Marsch WC, Haerting J, Helmbold P. Concomitant traumas influence prognosis in melanomas of the nail apparatus. Br J Dermatol. 2006;155:76-80.

  10. Rolón PA, Kramárová E, Rolón HI, Khlat M, Parkin DM. Plantar melanoma: a case-control study in Paraguay. Cancer Causes Control. 1997;8:850-6.

  11. O’Leary JA, Berend KR, Johnson JL, Levin LS, Seigler HF. Subungual melanoma: a review of 93 cases with identification of prognostic variables. Clin Orthop Relat Res. 2000;(378):206-12.

  12. Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in The United States, 1986- 2005. Arch Dermatol. 2009;145:427-34.

  13. Hazan C, Melzer K, Panageas AS, Li E, Kamino H, Kopf A. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer. 2002;95:634-40.

  14. Slingluff CL Jr, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer. 1992;70:1917-27.

  15. Soong ST, Weiss HL. Predicting outcome in patients with localized melanoma. En: Balch CM, Houghton AN, Sober AJ, Soong SJ, editores. Cutaneous melanoma. 3rd ed. St. Louis: Quality Medical Publishing, Inc.; 1998. p. 51-61.

  16. Morton DL, Davtyan DG, Wanek LA, Foshag LJ, Cochran AJ. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer. 1993;71:3737-43.

  17. Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta- analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153:477-91.

  18. Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016;2:16014.

  19. Antonescu CR, Leung DH, Dudas M, Ladanyi M, Brennan M, Woodruff JM, et al. Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol. 2000;156:977-83.

  20. Hoos A, Uris MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol. 2001;158:1245-51.

  21. Hoos A, Stojadinovic A, Singh B. Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol. 2002;160:175-83.

  22. Vishnevskaya Y, Martynkov D, Savelov N. Ki67 (MIB1) in differential diagnosis between naevi and melanomas. Eur J Cancer Supplements. 2007;5:400.

  23. Gimmoty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-56.

  24. Ladstein RG, Bachmann IM, Straume O, Akslen LA. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 2010;10:140.

  25. Chorny JA, Barr RJ, Kyshtoobayeva A, Jakowatz J, Reed RJ. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions. Mod Pathol. 2003;16:525-9.

  26. Rieger E, Hoffman-Wellenhof R, Soyer HP, Kofler R, Cerroni L, Smolle J, et al. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. J Cutan Pathol. 1993;20:229.

  27. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M, Stolz W. P53-protein and Ki-67 antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology. 1997;30:57.

  28. Korabiowska M, Brinck U, Middel P, Brinkmann U, Berger H, Radzun HJ, et al. Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance. Anticancer Res. 2000;20:1781.

  29. Li LXL, Crotty KA, McCarthy SW, Palmer AA, Kril JJ. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2000;22:489.

  30. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol. 2001;195 530.

  31. Kanter-Lewensohn L, Hedblad MA, Wejde J, Larsson O. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol. 1997;10:917-20.

  32. Ramsay JA, From L, Iscoe NA, Kahn HJ. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol. 1995;105:22-6.

  33. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res. 1999;5:2082-8.

  34. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst. 1998;90:1284-91.

  35. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000;6:1891-5.

  36. Herrera-González NE, Aco-Flores AY. El melanoma en México. Rev Esp Med Quir. 2010;15:161-4.

  37. Pozzobon F, Acosta A, Carreño A, Fierro A. Características del melanoma cutáneo primario en el Instituto Nacional de Cancerología 2006-2010. Rev Colomb Cancerol. 2013;17:111-8.

  38. Wu XC, Eide MJ, King J, Saraiya M, Huang Y, Wiggins C, et al. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S26-37.

  39. Väisänen A, Kuvaja P, Kallioinen M, Turpeenniemi-Hujanen T. A prognostic index in skin melanoma through the combination of matrix metalloproteinase- 2, Ki67, and p53. Hum Pathol. 2011;42:1103-11.

  40. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206.

  41. Vereecken P, Laporte M, Heenen M. Significance of cell kinetic parameters in the prognosis of malignant melanoma: a review. J Cutan Pathol. 2007;34:139-45.

  42. Schimming TT, Grabellus F, Roner M, Pechlivanis S, Sucker A, Bielefeld N, et al. pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas. Am J Dermatopathol. 2012;34:266-9.

  43. Nielsen PS, Riber-Hansen R, Jensen TO, Schmidt H, Steiniche T. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Mod Pathol. 2013;26:404-13.

  44. Garbe C, Eigentler TK, Bauer J, Blödorn-Schlicht N, Cerroni L, Fend F, et al. Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry. J Dtsch Dermatol Ges. 2016;14:910-5.




2020     |     www.medigraphic.com